Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, along with scientists from the Broad Institute of MIT and Harvard, will present advancements related to TfR1 CapX™. A leading...

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2...

Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

Ascletis Pharma Inc. announces completion of enrollment in its 13-week U.S. Phase II study (NCT07321678) evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the...

Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program

Orthogon Therapeutics announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus...

Recent Innovations Showcased by Baxter

Baxter International Inc. a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery portfolio of hemostatic and sealing agents. New...

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

Eton Pharmaceuticals, Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre...

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

US-Rx Care, the nation's first fiduciary pharmacy risk manager and an industry leader since 2007, is issuing an urgent strategic call-out to employers: the Pharmacy Benefit Manager (PBM) industry has reached a point of no return. After years of...

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

Merck known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan). Merck’s first-in-class oral...

Neurizon Begins Dosing of NUZ-001 in HEALEY ALS Platform Trial

Neurizon® Therapeutics Limited a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS...

SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

Clarity Pharmaceuticals a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that yet another participant with mCRPC in the...

PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

PureTech Health plc a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, announced that the U.S. Food and Drug Administration (FDA) and European Commission have granted Orphan Drug...

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

P-Cure, a supplier of compact, gantry-less proton therapy systems, announced the first-ever prospective clinical results demonstrating the feasibility, safety, and early efficacy of gantry-less upright proton therapy for lung cancer...

Breakthrough in Zika Virus Drug Discovery Reported by IRBM

IRBM, a leader in early drug discovery research, has announced a major scientific breakthrough with the discovery of a novel and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The findings, published in Nature...

A Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression.

A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" (Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G. Gene Expression Patterns in Lung Adenocarcinoma...

China approves Libevitug, first-in-class therapy for hepatitis D

Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated...

Alamar Biosciences announces the launch of the NULISAqpcr™ AD 5-plex assay, advancing blood-based biomarker detection for Alzheimer’s disease research

Alamar Biosciences, Inc. a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay. This innovative solution enables...

Clover Begins Phase 2 Clinical Evaluation of a Combination Respiratory Vaccine Targeting RSV, hMPV, and ± PIV3

Clover Biopharmaceuticals, Ltd. a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. Announced that enrollment of the first participants has...

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Shanghai Ark Biopharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Aizhida) for...

Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

Coya Therapeutics, Inc. a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced positive results of an investigator-initiated...

RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal...